Skip to content
Facebook Instagram Linkedin

LifeScienceHistory.com

History made daily

  • Home
  • DirectoryExpand
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • CareersExpand
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a RockExpand
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
LifeScienceHistory.com
History made daily
Home / Infectious Disease - Page 25

Infectious Disease

Moderna and Canada announced collaboration to bring mRNA manufacturing to Canada
Biotechnology | Infectious Disease | Vaccine

Moderna and Canada announced collaboration to bring mRNA manufacturing to Canada

On Aug. 10, 2021, Moderna announced a Memorandum of Understanding (MoU) with the government of Canada to build…

Read More Moderna and Canada announced collaboration to bring mRNA manufacturing to CanadaContinue

Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccine

On Aug. 9, 2021, Moderna announced that the Therapeutic Goods Administration (TGA) had granted provisional registration to the…

Read More Australian Therapeutic Goods Administration granted provisional registration for Moderna’s COVID-19 vaccineContinue

INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidate

On Aug. 9, 2021, Inovio Pharma announced that it had received regulatory allowance for two clinical trials investigating…

Read More INOVIO and Advaccine receive regulatory allowance for prime-boost clinical trials in China using INO-4800, COVID-19 DNA vaccine candidateContinue

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibody

On Aug. 5, 2021, Novavax announced preliminary data demonstrating that a single booster dose of its recombinant nanoparticle…

Read More Novavax announced COVID-19 vaccine booster data demonstrating four-fold Increase in neutralizing antibodyContinue

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccine

On Aug. 4, 2021, Novavax announced that it had reached an agreement with the European Commission (EC) for…

Read More Novavax and EC finalized advance purchase agreement for up to 200 million doses of COVID-19 vaccineContinue

Moderna received FDA Fast Track Designation for Respiratory Syncytial Virus vaccine
Biotechnology | FDA | Infectious Disease | Therapeutics | Vaccine

Moderna received FDA Fast Track Designation for Respiratory Syncytial Virus vaccine

On Aug. 3, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track…

Read More Moderna received FDA Fast Track Designation for Respiratory Syncytial Virus vaccineContinue

CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients
Biotechnology | COVID-19 | Infectious Disease | Therapeutics

CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patients

On Aug. 3, 2021, CytoDyn announced that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved…

Read More CytoDyn received clearance from Brazil’s FDA (ANVISA) to commence pivotal phase 3 trial in critically ill COVID-19 patientsContinue

Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine
Biotechnology | Diagnostics | Infectious Disease | Vaccine

Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccine

On Jul. 29, 2021, Vaxart announced that it has shown for the first time in clinical trials that…

Read More Vaxart reported boosting immune responses in subjects previously vaccinated by a Vaxart vaccineContinue

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical study

On Jul. 28, 2021, GlaxoSmithKline and Vir Biotechnology announced they had signed a Joint Procurement Agreement with the…

Read More Second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response and protection in preclinical studyContinue

Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines
Biotechnology | Infectious Disease | NIH | Vaccine

Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccines

On Jul. 27, 2021, Oragenics announced it had entered into a licensing agreement with the National Research Council…

Read More Oragenics entered into licensing agreement with the NRC of Canada, to pursue next-generation SARS-CoV-2 vaccinesContinue

CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU
Biotechnology | COVID-19 | Infectious Disease | Vaccine

CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EU

On Jul. 23, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read More CHMP adopted positive opinion recommending authorization for use of the Moderna COVID-19 vaccine in adolescents in EUContinue

Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster
Biotechnology | COVID-19 | Infectious Disease | Life Science History | Therapeutics | Vaccine

Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant booster

On Jul. 22, 2021, Moderna announced a new supply agreement with Taiwan for 20 million doses of Moderna’s…

Read More Moderna announced agreement with Taiwan for 20 million doses of Moderna’s COVID-19 Vaccine and variant boosterContinue

Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidate

On Jul. 20, 2021, Moderna announced that the Ministry of Health, Labour and Welfare of Japan (MHLW) and…

Read More Moderna partnered with Takeda and Government of Japan to aupply additional 50 million doses of COVID-19 vaccine and variant booster candidateContinue

CDC and Texas confirmed Monkeypox In U.S. traveler
Biotechnology | CDC | Diagnostics | Infectious Disease | Therapeutics

CDC and Texas confirmed Monkeypox In U.S. traveler

On Jul. 16, 2021, the U.S. Centers for Disease Control and Prevention (CDC) announced and the Texas Department…

Read More CDC and Texas confirmed Monkeypox In U.S. travelerContinue

Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine | WHO

Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccine

On Jul. 12, 2021, Moderna announced a supply agreement with the government of Argentina for 20 million doses…

Read More Moderna announced supply agreement with Argentina for 20 million doses of its COVID-19 vaccineContinue

Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMA
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMA

On Jul. 1, 2021, Moderna confirmed that following the European Medicines Agency’s (EMA) Committee for Human Medicines (CHMP)…

Read More Moderna announced Recipharm site in France manufacturing COVID-19 Vaccine following approval by EMAContinue

Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacy

On Jun. 30, 2021, Novavax announced the publication of results from the final analysis of a pivotal Phase…

Read More Novavax published results of UK phase 3 clinical trial demonstrating high levels of COVID-19 vaccine efficacyContinue

Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)
Biotechnology | Infectious Disease | Vaccine

Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)

On Jun. 29, 2021, Paratek Pharmaceuticals announced it had delivered the first procurement of NUZYRA to the Biomedical…

Read More Paratek announced first BARDA Project BioShield procurement of NUZYRA (omadacycline)Continue

Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants

On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…

Read More Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variantsContinue

Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of India
Biotechnology | COVID-19 | Infectious Disease | Vaccine | WHO

Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of India

On Jun. 29, 2021, Moderna announced that the government of India had issued a registration certificate and a…

Read More Moderna announces Emergency Use Authorization for its COVID-19 vaccine granted by Government of IndiaContinue

European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022
Biotechnology | COVID-19 | Infectious Disease | Vaccine

European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022

On Jun. 22, 2021, Moderna announced that the European Commission (EC) had purchased an additional 150 million doses…

Read More European Commission purchased additional 150 million doses of Moderna’s COVID-19 vaccine for delivery in 2022Continue

Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndrome

On Jun. 21, 2021, Tonix Pharmaceuticals announced that it planned to develop TNX-102 SL (cyclobenzaprine HCl sublingual tablets)…

Read More Tonix Pharmaceuticals announced program to develop TNX-102 SL for treatment of long COVID syndromeContinue

U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccine

On Jun. 16, 2021, Moderna announced that the U.S. government had purchased an additional 200 million doses of…

Read More U.S. Government purchased additional 200 million doses of Moderna’s COVID-19 vaccineContinue

KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial
Biotechnology | COVID-19 | Infectious Disease | NIH | Vaccine

KPWHRI announced volunteers needed for COVID-19 vaccine-booster trial

On Jun. 16, 2021, Kaiser Permanente Washington Health Research Institute (KPWHRI) announced that was recruiting volunteers in the…

Read More KPWHRI announced volunteers needed for COVID-19 vaccine-booster trialContinue

Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates
Biotechnology | COVID-19 | Infectious Disease | Therapeutics | Vaccine

Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab Emirates

On Jun. 15, 2021, Moderna and Magenta Investments, an industrial conglomerate in the United Arab Emirates (UAE), announced…

Read More Moderna and Magenta partner to distribute Moderna’s COVID-19 vaccine in United Arab EmiratesContinue

University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration award
Biotechnology | COVID-19 | Diagnostics | Infectious Disease | Therapeutics | Vaccine

University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration award

On Jun. 14, 2021, University of British Columbia researchers Dr. Jayachandran Kizhakkedathu, Dr. Caigan Du and Dr. Christopher…

Read More University of British Columbia researchers received the New Frontiers in Research Fund 2020 Exploration awardContinue

Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Moderna submitted authorization application for its COVID-19 vaccine in adolescents in Switzerland

On Jun. 14, 2021, Moderna announced that it had submitted an authorization application to Swissmedic for use of…

Read More Moderna submitted authorization application for its COVID-19 vaccine in adolescents in SwitzerlandContinue

Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial
Biotechnology | COVID-19 | Infectious Disease | Nanotechnology | Vaccine

Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trial

On Jun. 14, 2021, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against…

Read More Novavax COVID-19 vaccine demonstrated 90% overall efficacy and 100% protection in phase 3 trialContinue

Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously
Biotechnology | Infectious Disease | Influenza | Vaccine

Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneously

On Jun. 14, 2021, Novavax announced data from the first co-administration study of a SARS-CoV-2 vaccine candidate [Novavax,…

Read More Novavax announced positive results from study of influenza vaccine and COVID-19 vaccine candidate administered simultaneouslyContinue

Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccine
Biotechnology | COVID-19 | Infectious Disease | Vaccine

Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccine

On Jun. 11, 2021, Novavax announced preclinical and clinical data on the company’s original recombinant protein COVID-19 vaccine…

Read More Novavax announces positive data from three complementary studies of COVID-19 Beta variant strain vaccineContinue

Page navigation

Previous PagePrevious 1 … 23 24 25 26 27 … 59 Next PageNext
  • Categories
  • Timeline
  • Agriculture
  • Artificial Intelligence
  • Biology
  • Biotechnology
  • Cartoons – Historical
  • Cartoons – Original
  • CDC
  • CDMO
  • Chemical
  • Cloning
  • CMO
  • COVID-19
  • CRISPR
  • CRO
  • Cryogenic
  • Dentistry
  • Diagnostics
  • Disease
  • Energy
  • Environmental
  • EPA
  • FDA
  • Forestry
  • Genomics
  • HIV
  • Infectious Disease
  • Influenza
  • IRB
  • Life Science History
  • Marine Science
  • Materials
  • Measles
  • Medical Device
  • Medicine
  • Nanotechnology
  • Neurology
  • NIH
  • Non-Profit Research
  • Nutraceuticals
  • Oncology
  • Ophthalmogy
  • Organ Transplant
  • Orthopedic
  • Other
  • Pharmaceutical
  • Plague
  • Polio
  • Prehistory
  • Radiology
  • Rare Disease
  • Stem Cell
  • Therapeutics
  • U.S. Congress
  • Uncategorized
  • USDA
  • Vaccine
  • Veterinary
  • WHO
  • Women's Health
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001
  • 2000
  • 1999
  • 1998
  • 1997
  • 1996
  • 1995
  • 1994
  • 1993
  • 1992
  • 1991
  • 1990
  • 1989
  • 1988
  • 1987
  • 1986
  • 1985
  • 1984
  • 1983
  • 1982
  • 1981
  • 1980
  • 1979
  • 1978
  • 1977
  • 1976
  • 1975
  • 1974
  • 1973
  • 1972
  • 1971
  • 1970
  • 1969
  • 1968
  • 1967
  • 1966
  • 1965
  • 1964
  • 1963
  • 1962
  • 1961
  • 1960
  • 1959
  • 1958
  • 1957
  • 1956
  • 1955
  • 1954
  • 1953
  • 1952
  • 1951
  • 1950
  • 1949
  • 1948
  • 1947
  • 1946
  • 1945
  • 1944
  • 1943
  • 1942
  • 1941
  • 1940
  • 1939
  • 1938
  • 1937
  • 1936
  • 1935
  • 1934
  • 1933
  • 1932
  • 1931
  • 1930
  • 1929
  • 1928
  • 1927
  • 1926
  • 1925
  • 1924
  • 1923
  • 1922
  • 1921
  • 1920
  • 1919
  • 1918
  • 1917
  • 1916
  • 1915
  • 1914
  • 1913
  • 1912
  • 1911
  • 1910
  • 1909
  • 1908
  • 1907
  • 1906
  • 1905
  • 1904
  • 1903
  • 1902
  • 1901
  • 1900
  • 1899
  • 1898
  • 1897
  • 1896
  • 1895
  • 1894
  • 1893
  • 1892
  • 1891
  • 1890
  • 1889
  • 1888
  • 1887
  • 1886
  • 1885
  • 1884
  • 1883
  • 1882
  • 1881
  • 1880
  • 1879
  • 1878
  • 1877
  • 1876
  • 1875
  • 1874
  • 1873
  • 1872
  • 1871
  • 1870
  • 1869
  • 1868
  • 1867
  • 1866
  • 1865
  • 1864
  • 1863
  • 1862
  • 1861
  • 1860
  • 1859
  • 1858
  • 1857
  • 1856
  • 1855
  • 1854
  • 1853
  • 1852
  • 1851
  • 1850
  • 1849
  • 1848
  • 1847
  • 1846
  • 1845
  • 1844
  • 1843
  • 1842
  • 1840
  • 1839
  • 1838
  • 1837
  • 1836
  • 1834
  • 1833
  • 1832
  • 1831
  • 1830
  • 1828
  • 1827
  • 1826
  • 1825
  • 1824
  • 1823
  • 1820
  • 1819
  • 1818
  • 1817
  • 1816
  • 1813
  • 1811
  • 1810
  • 1809
  • 1808
  • 1804
  • 1802
  • 1801
  • 1800
  • 1799
  • 1798
  • 1796
  • 1795
  • 1794
  • 1793
  • 1790
  • 1789
  • 1788
  • 1786
  • 1785
  • 1784
  • 1782
  • 1781
  • 1777
  • 1769
  • 1765
  • 1761
  • 1753
  • 1751
  • 1749
  • 1747
  • 1746
  • 1743
  • 1741
  • 1738
  • 1727
  • 1723
  • 1721
  • 1720
  • 1718
  • 1716
  • 1712
  • 1697
  • 1693
  • 1683
  • 1674
  • 1667
  • 1666
  • 1665
  • 1664
  • 1663
  • 1658
  • 1656
  • 1647
  • 1636
  • 1634
  • 1629
  • 1621
  • 1603
  • 1580
  • 1521
  • 1510
  • 1403
  • 1377
  • 1370
  • 1363
  • 1348
  • 1346
  • 1322
  • 1285
  • 1202
  • 1200
  • 1179
  • 1100
  • 1050
  • 541
  • 470
  • 1
Subscribe to E-History

Subscribe

* indicates required

LifeScienceHistory.com

LifeScienceHistory.com Where history is made daily, is a comprehensive companion of life science. Simply put, we dig history and we mine data.

More

  • About
  • Life Science Heroes

Advertising

  • Life Science Banner Advertising
  • Advertise Your Life Science Jobs

Legal

  • Privacy Policy
  • Terms of Use

© 2025 LifeScienceHistory.com by James Web Design

Facebook Instagram Linkedin
  • Home
  • Directory
    • General Company Directory
    • CRO Directory
    • CMO Directory
    • Genealogy on Demand
  • Careers
    • Find Your Job
    • Advertise Your Life Science Jobs
  • News and History
  • Cartoons
  • Small World
  • Earth is a Rock
    • Earth is a Rock
    • Earth is a Rock Lyrics
    • Earth is a Rock Lyrics Defined
Search